← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

BRAF Mutant Thyroid Cancer

MONDO:0005075 Curated 2026-07-04T00:00:00Z 8 harmonized findings
falcon · 56 citations openscientist · 80 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

BRAF-mutant papillary thyroid cancer is driven by a somatic BRAF V600E (c.1799T>A, p.Val600Glu) missense mutation in thyroid follicular cells that constitutively activates the RAS-RAF-MEK-ERK (MAPK) signaling cascade independent of upstream receptor tyrosine kinase input.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% constitutively activates RAF kinase signaling and is the predominant BRAF alteration in PTC
Falcon states the V600E hotspot (c.1799T>A, p.Val600Glu) constitutively activates RAF/MAPK signaling and is the predominant driver alteration in PTC.
DOI:10.1002/hed.27950
openscientist CONCORDANT 97% The BRAF V600E mutation occurs as a somatic (acquired) event in thyroid follicular cells and results in constitutive activation of the MAPK signaling pathway independent of upstream receptor tyrosine kinase stimulation.
OpenScientist gives the identical mechanism and adds the somatic origin and the RTK-independence of the constitutive MAPK activation.
PMID:39961465

Constitutive MAPK output from BRAF V600E suppresses thyroid differentiation genes, most critically the sodium-iodide symporter (NIS/SLC5A5), driving radioactive iodine (RAI) refractoriness in a large fraction of tumors.

UNANIMOUS INTEGRATED
pathophysiologytreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% High MAPK output from BRAFV600E suppresses thyroid-differentiation genes and impairs
Falcon describes MAPK-driven suppression of differentiation genes and impaired NIS/SLC5A5 expression as the basis for loss of iodine uptake and RAIR disease (5-15% of DTCs, ~50% of metastatic DTCs).
DOI:10.3389/fendo.2024.1346476
openscientist CONCORDANT 95% The mutation suppresses thyroid differentiation genes, most critically the sodium-iodide symporter (NIS/SLC5A5), leading to radioactive iodine (RAI) refractoriness in up to 60% of BRAF-mutant PTC.
OpenScientist asserts the same NIS-suppression mechanism and quantifies RAI refractoriness at up to 60% of BRAF-mutant PTC.
PMID:41694580

Co-occurring TERT promoter mutation acts synergistically with BRAF V600E to markedly increase the risk of RAI refractoriness, recurrence, and dedifferentiation, making the double-mutant a high-risk molecular subset.

UNANIMOUS INTEGRATED
genetic_factorprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 85% are repeatedly highlighted as strong adverse prognostic markers in DTC and interact negatively with BRAFV600E
Falcon frames TERT promoter mutations as strong adverse prognostic markers that interact negatively with BRAF V600E, with RAIR at 82.4% in the BRAF+TERT double-mutant versus 6.3% in BRAF V600E alone.
DOI:10.1038/s41598-024-75087-9
openscientist CONCORDANT 90% Coexisting BRAF V600E + TERT independently elevates risk of loss of RAI avidity (OR=4.8, P=.009) and accelerates recurrence
OpenScientist quantifies the synergy (OR=4.8 for loss of RAI avidity) and ties it to accelerated recurrence and the dedifferentiation cascade toward anaplastic thyroid carcinoma.
PMID:40988283

Short-course BRAF/MEK inhibition (e.g., dabrafenib plus trametinib) is a redifferentiation strategy that can restore NIS expression and radioiodine uptake in BRAF V600E RAI-refractory tumors, enabling salvage I-131 therapy.

UNANIMOUS INTEGRATED
treatmentpathophysiology
ProviderStanceScoreEvidence
falcon CONCORDANT 88% Short-course inhibition of BRAFV600E/MAPK can restore NIS expression/iodine uptake in some RAIR tumors, enabling salvage RAI.
Falcon describes the MERAIODE-style redifferentiation concept (uptake restored in 20/21 evaluable patients) but cautions real-world BRAF-mutant redifferentiation is incomplete (38.9% vs 100% for RAS-mutant tumors).
DOI:10.3390/jcm13237021
openscientist CONCORDANT 92% BRAF/MEK inhibitor redifferentiation therapy with dabrafenib-trametinib restores RAI uptake from 5% to 95% of lesions in refractory patients
OpenScientist reports the pivotal phase II redifferentiation result (RAI uptake restored from 5% to 95% of lesions) for the same dabrafenib-trametinib strategy.
PMID:37074727

For RAI-refractory differentiated thyroid cancer, multikinase inhibitors — lenvatinib and sorafenib as first-line and cabozantinib as a later-line option — are standard systemic therapy that prolongs progression-free survival.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 80% Multiple contemporary reviews agree that for RAIR differentiated thyroid cancer:
Falcon's systemic-therapy section designates lenvatinib and sorafenib as standard first-line multitargeted TKIs and cabozantinib as the standard second-line option after progression, matching OpenScientist.
DOI:10.3390/life14010022
openscientist CONCORDANT 90% multikinase inhibitors (lenvatinib, sorafenib, cabozantinib) extend progression-free survival in advanced disease
OpenScientist names the same three multikinase inhibitors and, in its treatment tables, reports the SELECT, DECISION, and COSMIC-311 PFS benefits.
PMID:34237250

BRAF V600E anaplastic/dedifferentiated thyroid cancer responds strongly to combined kinase-inhibitor plus anti-PD-1 immunotherapy, reflecting a BRAF-associated immune microenvironment amenable to immune targeting.

MAJORITY LEAD
treatmentpathophysiology
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% Kinase inhibitors + anti-PD-1 achieved mOS not reached for BRAF V600E ATC vs. 4.0 months for non-BRAF (P=0.049); ORR 61.1%
OpenScientist reports quantitative immunotherapy-plus-targeted-therapy efficacy specifically in BRAF V600E ATC (ORR 61.1%, mOS not reached).
PMID:39395384
falcon PARTIAL 40% experimental inhibition of CXCR2 or repression of MDSCs improved the effect of MAPK inhibitor therapy in advanced thyroid cancer models
Falcon establishes the BRAF V600E-driven immunosuppressive microenvironment (TBX3-CXCR2 ligand axis recruiting MDSCs) and a rationale for combining MAPK inhibition with immune-microenvironment targeting, but does not report the checkpoint-immunotherapy clinical efficacy in BRAF V600E ATC that OpenScientist quantifies. Partial: mechanistic rationale without the outcome.
DOI:10.1038/s41467-022-29000-5

Although BRAF V600E is associated with aggressive clinicopathologic features (lymph node metastasis, extrathyroidal extension), overall prognosis of BRAF-mutant PTC remains excellent and BRAF status alone has limited independent prognostic value after multivariable adjustment.

UNANIMOUS INTEGRATED
prognosisphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 85% Brumfield 2025 found no independent association with recurrence in multivariable analysis
Falcon emphasizes that BRAF V600E did not independently predict recurrence (HR 0.71; p=0.4) once clinicopathologic factors were accounted for, arguing BRAF is best interpreted alongside stage, histology, and co-mutations.
DOI:10.1007/s12022-025-09859-y
openscientist CONCORDANT 80% the overall prognosis of BRAF-mutant PTC remains excellent (10-year disease-specific survival ~97.2%), particularly for localized disease
OpenScientist concurs the overall prognosis is excellent (10-year DSS ~97.2%) with only borderline increased recurrence risk (OR=1.56, 95% CI 1.00-2.41), consistent with limited stand-alone prognostic weight for BRAF status.
PMID:41817109

BRAF V600E is the most common oncogenic driver in PTC (roughly 40-80% across cohorts) and is strongly enriched in classic and tall-cell variants relative to follicular-patterned tumors.

UNANIMOUS INTEGRATED
epidemiologygenetic_factorphenotype
ProviderStanceScoreEvidence
falcon CONCORDANT 90% with enrichment by morphology (classic 88%, extensive follicular growth 38%, tall cell 100%)
Falcon reports the 78.7% single-institution BRAF V600E prevalence with strong subtype enrichment (classic 88%, follicular 38%, tall cell 100%).
DOI:10.1007/s12022-025-09859-y
openscientist CONCORDANT 90% A 2025 single-institution study found 78.7% of 301 PTC patients harbored BRAF V600E
OpenScientist cites the same 2025 cohort (78.7% of 301 patients) and the same subtype enrichment figures (88% classic, 100% tall cell, 38% follicular) — a genuine shared-study convergence despite otherwise distinct bibliographies.
PMID:40237893

Narrative

Overview

Both providers frame BRAF-mutant papillary thyroid cancer as a molecularly defined subtype of differentiated thyroid carcinoma driven by the somatic BRAF V600E (c.1799T>A, p.Val600Glu) mutation, which constitutively activates the MAPK/ERK cascade, suppresses thyroid differentiation and NIS/SLC5A5, and drives radioiodine refractoriness. Falcon is a focused, mechanism- and RAIR/redifferentiation-centric report (~20-22 cited sources) while OpenScientist is a comprehensive 15-domain characterization (~80 sources) with deeper epidemiology, prognosis, immunotherapy, and multi-omic detail.

Agreement

The reports converge on the core biology and management: somatic BRAF V600E as the constitutive MAPK driver; MAPK-mediated suppression of differentiation genes and NIS causing RAI refractoriness; BRAF V600E + TERT promoter synergy as the high-risk molecular subset; BRAF/MEK-inhibitor redifferentiation (dabrafenib-trametinib) restoring iodine uptake; lenvatinib/sorafenib first-line and cabozantinib later-line multikinase therapy for RAIR-DTC; and subtype enrichment of BRAF V600E in classic and tall-cell PTC. Notably both independently cite the same 2025 Brumfield cohort (78.7% prevalence; 88% classic, 100% tall cell, 38% follicular), and both temper BRAF's stand-alone prognostic value.

Divergence

Coverage and recency differ more than substance. OpenScientist adds quantitative epidemiology (GBD trends, ~25% global overdiagnosis), a formal excellent-prognosis frame (10-year DSS ~97.2%), active-surveillance safety data, single-cell immune-trajectory and resistance biology (TAZ/Hippo, fatty- acid-oxidation epigenetic reprogramming, RAS feedback), and quantitative immunotherapy efficacy in BRAF V600E ATC (ORR 61.1%). Falcon contributes a tighter mechanistic and RAIR/redifferentiation account, the BRAF V600E-TBX3- CXCR2-MDSC immunosuppression axis, SWI/SNF-loss chromatin resistance, SEER incidence-trend inflection points aligned with ATA guideline revisions, and a curated ClinicalTrials.gov trail. No direct contradictions were found; the ATC immunotherapy finding is the clearest divergence (OpenScientist quantifies the clinical benefit; Falcon supplies only the immune-microenvironment rationale).

Integration

Promotable to kb/disorders/BRAF_Mutant_Thyroid_Cancer.yaml: the BRAF V600E constitutive-MAPK driver node; the MAPK -> differentiation-gene/NIS suppression -> RAI-refractoriness chain; BRAF+TERT synergy as an adverse genetic/prognostic modifier; BRAF/MEK-inhibitor redifferentiation and multikinase-inhibitor treatments; the subtype-enrichment/prevalence epidemiology; and the excellent-overall-prognosis-with-limited-independent-BRAF-value framing.

Not integrated (leads)

Retained as leads rather than promoted mechanisms: the BRAF V600E ATC immunotherapy efficacy (advanced/ATC-specific, single-source quantitation), preclinical resistance pathways (TAZ/Hippo, FAO epigenetic reprogramming, RAS feedback, SWI/SNF loss), single-cell/spatial multi-omic trajectories, overdiagnosis and active-surveillance epidemiology, and specific ClinicalTrials.gov entries — all pending primary-source verification before becoming curated evidence.

Cross-provider synthesis comparing the falcon (mechanism/RAIR-focused) and openscientist (comprehensive 15-domain) BRAF-mutant PTC reports. mondo taken from kb/disorders/BRAF_Mutant_Thyroid_Cancer.yaml (disease_term MONDO:0005075). All best_matching_text values are verbatim excerpts from the two report files; no literature evidence blocks or ontology terms are asserted here — that is the job of the disorder-YAML curation pipeline. Consensus is derived, not authored.